Table of Contents
Overview
Definition of Biomanufacturing
Biomanufacturing, also known as bioproduction, is a manufacturing process that employs biological systems, including living microorganisms, animal cells, plant cells, and enzymes, to produce commercially significant biomaterials and biomolecules. These products are utilized across various sectors, including pharmaceuticals, food and beverage processing, and industrial applications.[3.1] The core of most biomanufacturing processes involves fermentation in a bioreactor, where raw materials are transformed into target products through the catalytic action of enzymes or biological cells.[2.1] Biomanufacturing is defined as the use of biological systems, including living microorganisms, resting cells, animal cells, plant cells, tissues, enzymes, or in vitro synthetic systems, to produce commercially important biomolecules for various industries, such as agriculture, food, materials, energy, and pharmaceuticals.[3.1] This process typically involves fermentation in a bioreactor, where raw materials are converted into target products through the catalysis of enzymes or biological cells.[2.1] The significance of biomanufacturing is underscored by its potential to create value-added products from renewable resources, thereby contributing to sustainability and reducing dependence on non-renewable resources.[2.1] The concept of Biomanufacturing 4.0 highlights the development of innovative products, such as human tissues and cells for regenerative medicine, as well as artificial starch produced by in vitro synthetic biosystems and isobutanol generated through metabolic engineering.[4.1] This new era of biomanufacturing aims to address emerging product needs, including renewable energy and artificial food, while leveraging advanced research tools like induced pluripotent stem cells, metabolic engineering, and synthetic biology to enhance production efficiency and sustainability.[4.1] As the field progresses, there is an increasing demand for fully controlled continuous biomanufacturing processes that can produce biofuels and commodity chemicals at significantly lower costs, highlighting the ongoing relevance and potential of biomanufacturing in addressing contemporary challenges.[2.1]Importance and Applications
Biomanufacturing plays a crucial role in the production of various biological products, including human tissues and organs, through innovative techniques and methodologies. One significant application of biomanufacturing is in the field of synthetic biology, which provides powerful tools for designing and modifying microorganisms to function as cell factories. This approach is essential for achieving sustainable chemical production and enhancing the efficiency of biomanufacturing processes.[7.1] The selection of suitable microorganisms or enzymes for specific biomanufacturing processes is influenced by two critical factors: medium compositions and cultivation conditions. These factors significantly affect the production of valuable compounds, such as bacteriocins, during the fermentation of various lactic acid bacteria (LAB) strains.[8.1] Additionally, omics data can accurately reflect the metabolic rearrangements caused by changes in the microenvironment and help explore the factors affecting the manufacturing performance of microorganisms at a microscopic level, including temperature, dissolved oxygen, pH, precursor supply, and substrate/product inhibition.[6.1] The availability of a diverse range of complex media for the cultivation of LAB further enhances the potential for optimizing these biomanufacturing processes.[8.1] In the field of regenerative medicine, the integration of synthetic biology into biomanufacturing is transforming the production of human tissues and cells. Recent advancements in synthetic cell models have demonstrated their utility in biotechnology, particularly in applications such as cancer targeting and antigen presentation. These models have enabled the assembly of three-dimensional structures with controlled intercellular interactions, thereby facilitating the creation of tissue-like architectures.[10.1] Furthermore, the workflow of recombinant protein biomanufacturing has been enhanced through the careful integration of steps that affect the efficiency, quality, purity, and quantity of protein products. Synthetic biology provides unique tools for engineering cells, which optimizes protein production and improves the overall quality of biomanufactured products.[9.1] This approach, which emphasizes synthetic extracellular matrix integration, synthetic cell self-organization, and adaptive biomechanics, holds significant potential for scalable synthetic tissue engineering, ultimately advancing both regenerative medicine and drug development.[10.1] The challenges of scalability and affordability significantly hinder the equitable deployment of curative models of care, despite advancements in regenerative medicine therapeutics. To address these issues, it is essential to enhance the availability and accessibility of new classes of biotherapeutics.[30.1] The integration of digitalization, biologicalization, and biomanufacturing has led to the emergence of a concept known as "bio-intelligent value addition," or more prominently, Bioprocessing 4.0. This innovative approach is transforming the landscape of biomanufacturing, enabling more effective solutions to the challenges faced in the production of complex tissues and organs.[31.1]History
Early Developments in Biomanufacturing
The history of biomanufacturing is marked by several key milestones that have significantly influenced current practices and shaped the regulatory landscape for biopharmaceuticals. The production of biopharmaceuticals began to gain traction with the approval of the first biopharmaceutical in 1982, which marked a pivotal moment in the industry. This event catalyzed the growth of the biopharmaceutical market, which has expanded significantly since then, reflecting advancements in recombinant DNA technology and the scientific maturity of manufacturing processes.[43.1] Biomanufacturing utilizes biological systems, including microorganisms and enzymes, to produce commercially important biomolecules across various industries, including pharmaceuticals, agriculture, and energy.[70.1] The evolution of biomanufacturing processes has been characterized by a transition from early methods that relied on simple biological systems to more sophisticated techniques that incorporate advanced engineering and technological innovations. For instance, the development of statins exemplifies this progression, showcasing the shift from first-generation statins produced by microorganisms to second-generation statins created through bioconversion, and finally to third-generation statins developed via chemoenzymatic synthesis.[71.1] As the industry has matured, the need for consistent and reproducible manufacturing processes has become paramount. The current biopharmaceutical industry adheres to high standards for product efficacy, quality, and safety, which have been established through rigorous regulatory frameworks set forth by organizations such as the FDA and EMA.[72.1] These frameworks have evolved in response to the complexities and challenges associated with scaling up biomanufacturing processes, which include maintaining product quality and optimizing production efficiency.[46.1] Moreover, the introduction of the Biomanufacturing Readiness Levels (BRL) framework has provided a systematic approach to assess the readiness of bioprocess technologies, further enhancing the industry's ability to innovate and adapt to emerging challenges.[48.1] As biomanufacturing continues to evolve, timely investments in continuous biomanufacturing practices are anticipated to improve production capabilities, reduce costs, and meet the growing demand for biologics.[45.1]Evolution of Techniques and Technologies
The evolution of biomanufacturing techniques and technologies has been significantly influenced by advancements in recombinant DNA technology, which has enabled the production of complex therapeutic molecules. The first biopharmaceutical, insulin, was developed by Genentech in 1982 using recombinant DNA technology, marking a pivotal moment in the industry. Since then, over 300 biologics have been approved for use, showcasing the rapid growth and innovation within this field.[51.1] Escherichia coli has played a crucial role in this evolution, particularly with the production of insulin as the first recombinant protein, which revolutionized diabetes treatment.[52.1] The application of recombinant DNA technology has facilitated the optimization of cell expression systems, allowing for the targeted production of specific proteins and improving the pharmacokinetics and therapeutic potential of biopharmaceuticals.[50.1] The development of large-scale mammalian cell culture processes has also been foundational, with early work in non-recombinant production of viral vaccines and antibiotics informing the biopharmaceutical industry. By 2009, a consensus production process for monoclonal antibodies (mAbs) emerged, which included cell culture in stirred tank bioreactors followed by various purification steps, ensuring acceptable yields and purity levels.[53.1] Despite these advancements, scaling up biomanufacturing processes presents challenges, particularly in maintaining product quality and consistency. As production scales, it is essential to ensure that cell lines can sustain high productivity and quality.[54.1] The complexities of scaling up are compounded by the need for regulatory compliance and the inherent unpredictability of biomanufacturing processes.[55.1] The integration of synthetic biology and metabolic engineering is fundamental to modern biomanufacturing, as these fields utilize biological systems to optimize the synthesis of target compounds, ranging from single-cell to large-scale fermentations.[56.1] However, to realize the full potential of these technologies, a significant challenge lies in transitioning from laboratory settings to commercial-scale operations.[57.1] Advocates of synthetic biology assert that overcoming this hurdle is essential for achieving the ambitions of sustainable biomanufacturing.[57.1]Recent Advancements
Continuous Bioprocessing
Continuous bioprocessing represents a significant advancement in the field of biomanufacturing, focusing on the need for fully controlled processes that enhance efficiency and reduce costs. This approach utilizes biological systems, such as enzymes and microorganisms, to produce a variety of products, including biofuels and high-value chemicals, from renewable resources. The core of most biomanufacturing processes is fermentation in a bioreactor, where raw materials are converted into target products through catalysis by biological agents.[81.1] The integration of continuous bioprocessing allows for a more streamlined production method compared to traditional batch processing. This shift is particularly crucial in the biopharmaceutical industry, which is under pressure to produce complex therapeutic molecules rapidly and consistently while maintaining high quality and cost-effectiveness.[84.1] Continuous processes can lead to improved product yields and reduced downtime, which are essential for meeting the growing demand for biomanufactured goods. Moreover, advancements in recombinant DNA technology play a pivotal role in continuous bioprocessing. This technology enables the combination of genetic material from various sources to express desired products in host cells, such as bacteria or yeast. The downstream processes involved in continuous bioprocessing include the separation and purification of bioproducts, ensuring that they meet stringent regulatory standards for safety and quality.[83.1] Biomanufacturing, also known as bioproduction, is a manufacturing process that leverages biological systems to create commercially significant biomaterials and biomolecules. These products are utilized in various sectors, including medicines, food and beverage processing, and industrial applications.[82.1] The biomanufacturing process often involves the recovery of products from natural sources, such as blood, or from cultures of microbes, animal cells, or plant cells that are cultivated in specialized equipment.[82.1] In response to the growing demand for skilled professionals in this field, several academic institutions have established curricula and facilities aimed at providing education and training in biomanufacturing. Notable institutions include the Golden LEAF Biomanufacturing Training and Education Center (BTEC) at North Carolina State University, the BRITE program at North Carolina Central University, and the North Carolina Community College System’s BioNetwork, all of which focus on workforce development for the biomanufacturing industry.[82.1]Innovations in Single-Use Technologies
Recent advancements in biomanufacturing have significantly transformed the landscape of production processes, particularly through the integration of automation and artificial intelligence (AI). Automation has replaced manual processes and batch production, leading to enhanced efficiency, reproducibility, and quality in biomanufacturing facilities.[85.1] The complexity of the biomanufacturing process necessitates robust process control, optimization, and monitoring to ensure product quality, which automation effectively addresses by enabling real-time control and reducing variability.[86.1] AI plays a pivotal role in optimizing biomanufacturing by predicting efficient methods for recycling waste products, thereby converting them into valuable byproducts. This not only enhances operational efficiency but also reduces costs and improves overall product quality.[87.1] The integration of AI into biomanufacturing processes is paving the way for innovative solutions that promise a more sustainable and productive future in biotechnology. Moreover, the application of life cycle assessment (LCA) is becoming increasingly important in evaluating the sustainability of biomanufacturing processes. LCA focuses on the environmental impact by analyzing energy and resource inputs alongside multiple environmental emissions, which helps biomanufacturers make informed decisions to minimize their ecological footprint.[119.1] By understanding the full lifecycle of their products, biomanufacturers can effectively reduce resource consumption and waste, contributing to a more sustainable future.[120.1] In particular, the assessment of CO2 emissions through LCA has been highlighted as a critical metric for evaluating the environmental impact of biomanufacturing processes. The ontological representation of LCA facilitates comparative analyses between manufacturing arrangements and their corresponding environmental outcomes.[121.1] Continuous biomanufacturing is hypothesized to be a key factor in reducing the environmental impact of biologics manufacturing, especially considering that HVAC energy consumption in cleanrooms significantly affects various impact categories.[122.1] These innovations in automation, AI, and sustainability assessments are collectively driving the evolution of biomanufacturing towards greater efficiency and environmental responsibility.Types Of Biomanufacturing
Medical Applications
Biomanufacturing plays a crucial role in the medical field by utilizing biological systems to produce essential biomolecules and materials for various applications. This process involves the use of living microorganisms, animal cells, and plant cells to manufacture products such as pharmaceuticals and nutraceuticals. Specifically, biomanufacturing can produce a wide range of medical products, including vaccines, antibodies, and other therapeutic agents, which are vital for treating diseases and improving health outcomes.[124.1] The core of most biomanufacturing processes in the medical sector is fermentation, which occurs in bioreactors. During fermentation, raw materials are converted into target products through the catalytic action of enzymes or biological cells. This method not only enhances the efficiency of production but also allows for the creation of complex biomolecules that are often difficult to synthesize through traditional chemical methods.[125.1] Moreover, advancements in biomanufacturing, such as Biomanufacturing 4.0, are paving the way for innovative medical applications. This includes the development of human tissues or cells through regenerative medicine and the production of biologically derived materials that can be used in various therapeutic contexts. These advancements are expected to significantly improve the quality and accessibility of medical treatments.[124.1]Food and Beverage Production
The process of fermentation plays a crucial role in food and beverage production, enhancing the nutritional value, flavor, and overall quality of food products. Fermentation improves the digestibility of proteins, carbohydrates, and fats, making nutrients more accessible to the body, which is essential for health and wellness.[126.1] Additionally, research has established correlations between specific fermented foods, such as kefir, kombucha, and various cheeses, and numerous health benefits, including weight management, improved cardiovascular health, and enhanced immune functions.[129.1] Precision fermentation, a method that utilizes metabolically engineered microorganisms, has emerged as a significant innovation in this field. This process allows for the production of flavoring and coloring agents in a controlled environment, thereby improving the performance and quality of food ingredients.[127.1] By employing systems metabolic engineering, researchers can construct strains that yield high levels of desired food components, which not only enhances flavor but also contributes to the safety and sustainability of food production.[128.1] Moreover, the growing consumer demand for healthier and more sustainable food options is driving innovations in biomanufacturing. As individuals become increasingly health-conscious and environmentally aware, food companies are adapting their product offerings to align with these preferences. This includes the incorporation of plant-based and allergen-friendly options, as well as leveraging technology to enhance the consumer experience.[139.1] The shift towards organic and plant-based foods reflects a broader trend in the food industry, where consumers are actively seeking products that resonate with their values regarding health and sustainability.[140.1]Regulatory And Technical Challenges
Compliance with Regulatory Standards
Regulatory compliance in biomanufacturing is a multifaceted challenge that necessitates adherence to stringent guidelines, such as current Good Manufacturing Practice (cGMP) standards, which mandate that biopharmaceutical products be manufactured in a reproducible and documented manner to ensure quality, safety, and efficacy.[165.1] Regulatory bodies, including the FDA, EPA, and USDA, are responsible for developing frameworks that not only address compliance issues but also foster innovation within the industry.[167.1] Data integrity is a critical component of regulatory compliance, as regulatory agencies require accurate and reliable data to assess the safety and efficacy of biopharmaceutical products.[168.1] The integration of new technologies, such as Artificial Intelligence (AI) and machine learning, into biomanufacturing processes presents both opportunities and challenges. While these technologies can enhance process analytics, they also raise concerns regarding data handling, documentation, and regulatory validation.[173.1] The adoption of Quality by Design (QbD) principles represents a systematic and proactive approach to integrating quality into the biopharmaceutical manufacturing process from its inception. This methodology aims to reduce product variability and defects, enhance development and manufacturing efficiencies, and improve overall product lifecycle management.[187.1] Regulatory compliance under QbD aligns with FDA and ICH guidelines, emphasizing a science- and risk-based approach alongside detailed documentation and proactive quality measures, which can potentially expedite regulatory reviews and approvals, such as Investigational New Drug (IND) and Biologics License Application (BLA) filings.[171.1] As the biopharmaceutical industry transitions from traditional fed-batch processes to Continuous Manufacturing (CM), it faces unique challenges in maintaining consistent product quality and compliance. Effective integration of risk management into process control strategies is essential to address these challenges, particularly in ensuring real-time quality control and microbial contamination management.[174.1] The implementation of sophisticated Process Analytical Technology (PAT) for product-specific Critical Quality Attributes (CQAs) is crucial, although regulatory validation of these tools for continuous processes remains a significant hurdle.[174.1] The integration of new technologies in biomanufacturing is crucial for ensuring compliance with Good Manufacturing Practice (GMP) standards; however, it can lead to gaps in data handling and documentation that need to be addressed.[170.1] To effectively manage these challenges, continuous training, robust data management systems, and stringent validation processes are essential to uphold high standards of data integrity.[170.1] Regulatory authorities are increasingly adopting adaptive and risk-based approaches to navigate the dynamic nature of biomanufacturing, which facilitates iterative assessments and encourages innovation while maintaining compliance with established standards.[169.1] Furthermore, implementing a robust Corrective and Preventive Action (CAPA) strategy is vital for systematically identifying, addressing, and preventing quality issues, thereby contributing to long-term quality improvement and compliance.[188.1] Quality Risk Management (QRM) is also integral to this process, as it systematically identifies, assesses, and controls risks to product quality throughout its lifecycle, which includes pharmaceuticals, biologics, medical devices, and clinical trial materials.[189.1] Overall, collaboration among stakeholders is essential to tackle complex issues and advance regulatory science, enabling the industry to address emerging challenges and drive progress in biomanufacturing.[169.1]Technical Barriers in Continuous Manufacturing
The transition from traditional batch manufacturing to continuous biomanufacturing presents several technical barriers that must be addressed to ensure successful implementation. One of the primary challenges is maintaining product quality and consistency throughout the continuous production process. As production scales, it is crucial that the cell line used can sustain high productivity and product quality, which can be difficult to achieve consistently in a continuous setting.[185.1] Moreover, the integration of advanced technologies and automation in continuous biomanufacturing requires sophisticated process control and monitoring systems. These systems must ensure real-time quality control and microbial contamination detection, which are essential for maintaining compliance with regulatory standards.[162.1] However, the validation of rapid testing technologies for continuous processes remains a significant hurdle, as regulatory agencies have specific requirements that must be met.[162.1] Despite the advantages of continuous manufacturing, such as increased efficiency and reduced capital costs, misconceptions about its complexity and suitability for large-scale production persist. These misunderstandings can hinder adoption rates within the conservative pharmaceutical industry, even though regulatory bodies have encouraged the transition.[183.1] Additionally, the high costs associated with current biologics manufacturing practices contribute to elevated drug prices, making timely investment in continuous biomanufacturing critical for improving production efficiency and cost-effectiveness.[184.1]Environmental Impact
Sustainability of Biomanufacturing
The sustainability of biomanufacturing is increasingly recognized as a critical factor in reducing the environmental impact of production processes. Experts from Thermo Fisher Scientific have highlighted that incorporating materials and equipment designed to minimize environmental impact is essential for achieving sustainability goals in biomanufacturing. This includes advancing the efficiency of products, reducing packaging needs, establishing regional supply chains, and promoting the recyclability of single-use technologies (SUTs).[206.1] Life cycle assessments (LCA) play a pivotal role in identifying areas for improvement in sustainability. By employing rigorous analyses such as LCA, biomanufacturers can significantly reduce energy consumption, water usage, and waste production.[207.1] The integration of sustainability as a formal design criterion can lead to substantial reductions in the environmental burden associated with biomanufacturing processes.[207.1] Recent literature reviews have focused on the technical feasibility, costs, and environmental impacts of biobased products compared to their fossil-based counterparts. These studies aim to identify bottlenecks in cost reduction and life cycle environmental impacts, providing valuable insights for stakeholders in the bioeconomy.[208.1] In the context of regulatory frameworks, the U.S. Environmental Protection Agency (EPA), the U.S. Food and Drug Administration (FDA), and the U.S. Department of Agriculture (USDA) have updated their regulations to support sustainable biomanufacturing practices. This initiative, in response to President Biden’s Executive Order 14081, aims to streamline oversight mechanisms for biotechnology products, ensuring safety while promoting innovation.[210.1] Challenges in biomanufacturing sustainability also include aligning financial incentives with technical capabilities and developing a skilled workforce. Coordinating educational efforts across various levels is essential to equip the workforce with critical skills necessary for advancing sustainable practices in biomanufacturing.[211.1] Innovative strategies such as the adoption of green chemistry, energy-efficient technologies, and circular economy principles are being implemented to enhance sustainability in biomanufacturing. These approaches not only reduce environmental impact but also improve production efficiency.[218.1] Furthermore, continuous biomanufacturing processes are gaining traction as a means to enhance productivity and reduce environmental impacts, positioning them as a cornerstone technology for a sustainable bioeconomy.[220.1]Reduction of Carbon Footprint
Single-use technologies (SUTs) have emerged as a significant advancement in biomanufacturing, contributing to a substantial reduction in the carbon footprint associated with these processes. The implementation of SUTs has been shown to decrease various environmental impacts, including electricity consumption by 30%, space requirements by 38%, steelwork by 62%, water usage by 87%, and cleaning materials by 95%.[213.1] This reduction in resource consumption is critical for achieving sustainability goals within the industry. The widespread adoption of single-use technology in biomanufacturing facilities indicates its potential to become the dominant platform in the sector.[214.1] These technologies facilitate process intensification, particularly when coupled with continuous processes, which further reduces energy requirements and overall facility carbon footprints.[215.1] Studies examining numerous combinations of product types, manufacturing technologies, and end-of-life options consistently demonstrate that SUTs present a lower overall environmental impact compared to traditional multiuse technologies. This is primarily due to their reduced water consumption, decreased use of cleaning chemicals, and lower energy requirements.[217.1] For instance, GE Healthcare's FlexFactory™ biomanufacturing operations in Marlborough, MA, exemplify the successful implementation of single-use technologies, showcasing their ability to minimize the overall environmental impact while addressing critical factors such as natural resource utilization, ecosystem quality, and human health.[216.1] As the biomanufacturing industry continues to evolve, the integration of single-use technologies is likely to play a pivotal role in enhancing sustainability and reducing the carbon footprint of production processes.In this section:
Future Trends
Digital Transformation in Biomanufacturing
The digital transformation in biomanufacturing is characterized by the integration of advanced technologies that enhance operational efficiency and product quality. Automation has revolutionized the bioprocessing industry by enabling real-time control of manufacturing processes, which reduces variability and improves product quality.[264.1] This shift towards automation is supported by industry leaders who have introduced innovative automated systems, such as perfusion systems and bioreactors, which facilitate this trend.[263.1] Moreover, the concept of Biomanufacturing 4.0 encompasses the use of artificial intelligence (AI), process interoperability, 3D printing, and big data analytics. These technologies contribute to creating a more connected, transparent, and customer-centric manufacturing environment.[265.1] As the industry evolves, there is a growing emphasis on continuous investment in learning and development to ensure that workforce skills align with these technological advancements.[254.1] The future of biomanufacturing will also see an increased reliance on digital tools and technologies, such as digital twins and process analytical technology (PAT) solutions, which are essential for optimizing processes and boosting productivity.[262.1] This integration of digital technologies is expected to play a significant role in shaping the biomanufacturing landscape by 2030, as organizations strive to achieve fully automated and environmentally friendly manufacturing facilities.[261.1]Emerging Technologies and Their Potential
Emerging technologies are poised to significantly influence the future of biomanufacturing, driving innovation and efficiency across the industry. The next-generation biomanufacturing market is projected to reach a value of USD 20 billion by the end of 2023, with expectations of growth at a compound annual growth rate (CAGR) of 7.2%, potentially doubling to USD 40 billion by 2033.[271.1] This growth is largely attributed to advancements in bioprocess optimization and digital biomanufacturing, which are anticipated to expand from $24.3 billion in 2024 to $39.6 billion in the coming years.[249.1] The biomanufacturing industry is poised for significant growth, with the global market for bioprocess optimization and digital biomanufacturing expected to increase from $24.3 billion in 2024 to $39.6 billion in the coming years. This expansion is largely driven by the industry's commitment to enhancing efficiency, minimizing human error, and enabling real-time monitoring and control of bioprocesses.[249.1] Key technological advancements, including single-use technology, continuous bioprocessing, automation, and digitalization, are critical factors contributing to this growth.[250.1] Furthermore, the future of biomanufacturing will necessitate innovative and flexible approaches to managing various biological systems, particularly in the context of vaccine production.[256.1] As the industry evolves, major investments will be required to bolster research and development capabilities, ensuring that facilities, manufacturing, engineering, and regulatory frameworks are adequately equipped to support Good Manufacturing Practices (GMP).[256.1] Overall, the integration of advanced bioreactor technology and artificial intelligence is expected to further enhance production capabilities, making the future of biomanufacturing promising.[256.1] The biomanufacturing landscape is also witnessing a trend towards increased collaboration between industry stakeholders and governmental bodies, aimed at fostering innovation and ensuring the resilience of supply chains. This strategic partnership is essential for addressing global challenges and enhancing national security through biomanufacturing.[258.1] Additionally, the rise of artificial intelligence (AI) in biomanufacturing processes is anticipated to streamline operations and improve decision-making, further solidifying the industry's future.[270.1] As the sector evolves, companies must strategically position themselves to capitalize on these emerging trends by investing in research and development, enhancing their manufacturing capabilities, and adapting to the regulatory landscape that supports good manufacturing practices (GMP).[270.1] The convergence of these technologies and strategies will not only drive economic growth but also position biomanufacturing as a critical component in addressing healthcare needs and sustainability challenges in the years to come.[258.1]In this section:
Case Studies
Successful Biomanufacturing Examples
Several notable case studies illustrate the successful application of innovative methodologies and technologies in biomanufacturing, particularly highlighting the role of Six Sigma and process intensification. One prominent example is the implementation of Six Sigma at Amgen, where the focus was on recombinant protein production. The company faced variability in cell culture and purification processes. By employing Six Sigma tools such as DMAIC (Define, Measure, Analyze, Improve, Control) and Statistical Process Control (SPC), Amgen achieved improvements in nutrient delivery, pH control, and chromatography, resulting in consistent yield and regulatory compliance.[294.1] Similarly, Genentech addressed inconsistent protein yield in its biologics manufacturing through Six Sigma methodologies, which included Design of Experiments (DOE) and regression analysis. This led to a 20% increase in yield and a reduction in defects by automating nutrient systems and controlling oxygen and temperature.[296.1] Pfizer's case in vaccine production further exemplifies the benefits of Six Sigma. The company tackled issues related to batch inconsistency and long cycle times by utilizing process mapping and control charts. These efforts resulted in reduced cycle times and improved batch consistency, showcasing the effectiveness of structured methodologies in enhancing operational efficiency.[296.1] Process intensification (PI) has emerged as a pivotal strategy in biomanufacturing, significantly enhancing productivity while minimizing costs and resource use. A case study illustrates the transition from a conventional 1000-L processing scheme to intensified processing at both 1000-L and 2000-L scales, demonstrating the potential for increased efficiency in production processes.[292.1] Specific techniques, such as single-use technologies, have been instrumental in this evolution, as they eliminate the need for extensive cleaning associated with traditional stainless-steel systems, thereby facilitating rapid changeovers and shorter production cycles.[316.1] Furthermore, the implementation of synergistic approaches in the biopharma sector has led to remarkable improvements, including increases in space-time yields by up to tenfold and reductions in production run times by 30%.[317.1] These advancements underscore the transformative impact of process intensification on the biomanufacturing landscape, enabling faster development of highly productive and cost-effective processes. Moreover, Merck's initiatives in biologics production highlight the critical importance of maintaining product quality and regulatory compliance. By integrating Six Sigma into their quality improvement strategies, Merck was able to address variability in purity and stability, ultimately enhancing product safety and compliance with regulatory standards.[298.1] This case underscores the necessity of robust quality control measures in the biomanufacturing sector, particularly in light of the stringent regulatory landscape.[297.1] These case studies collectively demonstrate the significant impact of structured methodologies and innovative technologies in overcoming challenges in biomanufacturing, leading to improved efficiency, cost-effectiveness, and compliance with regulatory requirements.Lessons Learned from Industry Leaders
The biomanufacturing industry has provided valuable lessons through various case studies, particularly in navigating regulatory challenges and implementing process improvements. One significant lesson is the importance of regulatory intelligence in enhancing compliance within biologics manufacturing. Companies have successfully managed regulatory complexities by adopting proactive planning strategies, which are crucial for maintaining product quality and ensuring compliance with evolving regulations.[303.1] Biopharmaceutical Contract Development and Manufacturing Organizations (CDMOs) have emerged as essential partners for biotech companies, facilitating the transition from preclinical development to clinical manufacturing. These organizations leverage their expertise in process development and scale-up manufacturing to mitigate regulatory risks while adhering to stringent guidelines that ensure product safety and quality.[304.1] The flexibility of CDMOs in adapting to market demands and production requirements has proven vital in overcoming regulatory hurdles.[304.1] The rapidly evolving field of biomanufacturing faces numerous regulatory challenges that impact all aspects of the industry, from product development to market approval. One of the most significant challenges is the rapid pace of scientific and technological advancement, which necessitates that regulatory agencies and stakeholders engage in ongoing debates about enhancing supply chain transparency and ensuring the reliability of biopharmaceutical production.[305.1] To effectively navigate this changing regulatory environment, it is essential for companies to prioritize internal alignment before engaging with regulatory agencies, particularly when adopting new approaches and emerging technologies.[306.1] Additionally, organizations are encouraged to embrace the education of regulatory agencies and the re-education of agency reviewers regarding legacy processes and unique products, which is crucial for maintaining compliance and product quality in this dynamic landscape.[306.1] Implementing Six Sigma methodologies in biomanufacturing has proven effective in addressing various operational challenges. For instance, Amgen faced variability in recombinant protein production, which they tackled using the DMAIC framework and statistical process control (SPC). This approach led to improvements in nutrient delivery and pH control, resulting in consistent yields and enhanced regulatory compliance.[309.1] Similarly, Genentech encountered issues with inconsistent protein yields during biologics manufacturing. By employing design of experiments (DOE) and regression analysis alongside SPC, they automated nutrient systems and optimized oxygen and temperature control, achieving a 20% increase in yield and a reduction in defects.[309.1] The DMAIC framework serves as a foundational tool for identifying areas of improvement and implementing data-driven solutions, demonstrating its effectiveness in reducing defect rates and streamlining processes within the industry.[310.1] Implementing Six Sigma can bring significant benefits to organizations, including improved efficiency, reduced defects, and enhanced overall customer satisfaction.[312.1] However, organizations often face various challenges during the integration of these methodologies. To effectively address these hurdles, it is essential to invest in training programs, provide access to necessary tools and software, and allocate dedicated resources to Lean Six Sigma projects.[313.1] By fostering a culture of change, focusing on data-driven decision-making, and maintaining a commitment to continuous improvement, organizations can successfully navigate the Lean Six Sigma journey and achieve lasting operational excellence.[313.1] This article will explore common challenges and offer strategies to help organizations overcome them, ensuring a smoother and more effective integration of Six Sigma principles into their operational processes.References
[2] Biomanufacturing - an overview | ScienceDirect Topics — Biomanufacturing is to use a biological system that consists of enzyme(s), microorganisms, or more advanced biological cells to make fuels, chemicals, nutraceuticals, pharmaceuticals, or other value-added products from renewable resources . Biomanufacturing is to use a biological system that consists of enzyme(s), microorganisms, or more advanced biological cells to make fuels, chemicals, nutraceuticals, pharmaceuticals, or other value-added products from renewable resources . For most biomanufacturing processes, fermentation in a bioreactor is the core unit, where the raw materials are converted into a target product with the catalysis by enzyme(s) or biological cells. There is an urgent need for fully controlled continuous biomanufacturing processes to make biofuels, commodity chemicals, and high-value products at significantly lower manufacturing cost.
[3] Biomanufacturing: history and perspective - PubMed — Biomanufacturing: history and perspective - PubMed Search in PubMed Search in PubMed Biomanufacturing is a type of manufacturing that utilizes biological systems (e.g., living microorganisms, resting cells, animal cells, plant cells, tissues, enzymes, or in vitro synthetic (enzymatic) systems) to produce commercially important biomolecules for use in the agricultural, food, material, energy, and pharmaceutical industries. Biomanufacturing 4.0 could focus on new products, for example, human tissues or cells made by regenerative medicine, artificial starch made by in vitro synthetic biosystems, isobutanol fermented by metabolic engineering, and synthetic biology-driven microorganisms, as well as exiting products produced by far better approaches. Keywords: Advanced biomanufacturing; Bioeconomy; Biomanufacturing 4.0; In vitro synthetic biosystem; Metabolic engineering and synthetic biology; Sustainability revolution. Search in PubMed
[4] Biomanufacturing: history and perspective - Oxford Academic — Biomanufacturing 4.0 could focus on new products, for example, human tissues or cells made by regenerative medicine, artificial starch made by in vitro synthetic biosystems, isobutanol fermented by metabolic engineering, and synthetic biology-driven microorganisms, as well as exiting products produced by far better approaches. In the beginning of this century, new product needs (e.g., renewable energy, artificial food, and regenerative medicines) and new research tools (such as, induced pluripotent stem cells (iPSC), metabolic engineering, synthetic biology, systems biology, cascade biocatalysis, etc.) would lead to a new revolution of biomanufacturing, which will produce new products (i.e., new functional tissues, new drugs) or produce existing products by far more effective means as compared to existing platforms in terms of product yield, volumetric productivity, product titer, scale-up feasibility, and sustainability.
[6] Current advances for omics-guided process optimization of microbial ... — These omics data can not only truly reflect the metabolism rearrangement caused by the microenvironment changes, but also help us explore the factors affecting the manufacturing performance of microorganisms at the microscopic level (temperature, dissolved oxygen, pH, precursor supply, substrate/product inhibition, etc.), achieving multi-scale
[7] Towards next-generation model microorganism chassis for biomanufacturing — Abstract Synthetic biology provides powerful tools and novel strategies for designing and modifying microorganisms to function as cell factories for biomanufacturing, which is a promising approach for realizing chemical production in a green and sustainable manner. Recent advances in genetic component design and genome engineering have enabled significant progresses in the field of synthetic
[8] Fermentation factors influencing the production of bacteriocins by ... — The effects of two important factors - medium compositions and cultivation conditions, which influence bacteriocin production during fermentation of various LAB strains 20 are discussed in this review. Effect of medium composition Complex media Abundant selection of complex media (CM) for the cultivation of LAB are available in today's market.
[9] Cell Factory Engineering: Challenges and Opportunities for Synthetic ... — The workflow of recombinant protein biomanufacturing involves careful integration of a series of steps affecting the efficiency, quality, purity, and quantity of the protein product. ... Synthetic biology provides a set of tools uniquely suited to engineer cells for optimizing protein ... Lee GM. 2021. Streamlined Human Cell-Based Recombinase
[10] Synthetic cells in tissue engineering - ScienceDirect — Synthetic cells in tissue engineering - ScienceDirect Synthetic cells in tissue engineering Open access Advanced synthetic cell models have already shown utility in biotechnology and immunology, including applications in cancer targeting and antigen presentation. Recent bottom-up approaches have also enabled synthetic cells to assemble into 3D structures with controlled intercellular interactions, creating tissue-like architectures. Here, we review recent advancements in synthetic cell-based tissue formation and introduce a three-pillar framework to streamline the development of synthetic tissues. This approach, focusing on synthetic extracellular matrix integration, synthetic cell self-organization, and adaptive biomechanics, could enable scalable synthetic tissues engineering for regenerative medicine and drug development. Next article in issue Recommended articles No articles found. For all open access content, the relevant licensing terms apply.
[30] PDF — Abstract Limited scalability and restricted affordability impede the equitable deployment of curative models of care despite advances achieved with regenerative medicine therapeutics. Mitigating the risk of widening health disparities mandates actions that would improve the availability and accessibility of new classes of biotherapeutics. Namely, the use of Smart Manufacturing empowered by
[31] Bioprocessing 4.0 in biomanufacturing: paving the way for ... - Springer — The promising amalgamation of digitalization, biologicalization, and biomanufacturing paved the way for an emerging concept of "bio-intelligent value addition" or more prominently Bioprocessing 4.0 that enables the transformation in the landscape of biomanufacturing.
[43] Biopharmaceutical Manufacturing: Historical Perspectives and Future ... — This review describes key milestones related to the production of biopharmaceuticals—therapies manufactured using recombinant DNA technology. The market for biopharmaceuticals has grown significantly since the first biopharmaceutical approval in 1982, and the scientific maturity of the technologies used in their manufacturing processes has grown concomitantly. Early processes relied on
[45] Developments and opportunities in continuous biopharmaceutical ... — ABSTRACT. Today's biologics manufacturing practices incur high costs to the drug makers, which can contribute to high prices for patients. Timely investment in the development and implementation of continuous biomanufacturing can increase the production of consistent-quality drugs at a lower cost and a faster pace, to meet growing demand.
[46] Scaling Up Biomanufacturing: Key Steps and Industry Challenges — However, this scaling process is complex and fraught with challenges, from maintaining product quality and consistency to optimizing production efficiency. For large-scale production, it’s crucial to ensure that the cell line can maintain high productivity and product quality during the scaling process. The actual scaling up of biomanufacturing begins once the cell culture and production process has been optimized at a small scale. One of the most significant challenges in scaling up biomanufacturing is ensuring that the product remains consistent and of high quality as production scales. While biomanufacturing technology has advanced significantly in recent years, there are still limitations when it comes to scaling up certain production processes. Guardar mi nombre, correo electrónico y sitio web en este navegador para la próxima vez que haga un comentario.
[48] Navigating Biomanufacturing Readiness Levels (BRL): A Comprehensive ... — The Biomanufacturing Readiness Levels (BRL) framework emerges as a beacon, providing a shared vocabulary and systematic approach to assess the readiness of bioprocess technologies. This comprehensive overview aims to delve into the intricacies of BRL, elucidating its significance, key components, assessment steps, and reflections on its future
[50] Biopharmaceutical development, production, and quality — With the help of recombinant DNA technology, it was possible to accelerate the discovery and production of candidate proteins, optimize cell expression systems, target specific proteins and genes, and improve pharmacokinetics and therapeutic potential .
[51] Biopharmaceutical Production by Recombinant DNA Technology: Future ... — Biopharmaceuticals are complex therapeutic molecules derived by recombinant deoxyribonucleic acid (rDNA) technology and produced from microbial cells (e.g., bacterial, yeast, insect, plant, or mammalian cell expression systems, and hybridomas). Insulin, the first biopharmaceutical, was developed by Genentech in 1982. In the last four decades, over 300 biologics have been approved for use in
[52] Escherichia coli in the production of biopharmaceuticals — Escherichia coli has shouldered a massive workload with the discovery of recombinant DNA technology. A new era began in the biopharmaceutical industry with the production of insulin, the first recombinant protein, in E. coli and its use in treating diabetes.
[53] Biopharmaceutical Manufacturing: Historical Perspectives and Future ... — Much of the foundational work for large-scale mammalian cell culture processes using both adherent and suspension cell lines was done for the non-recombinant production of viral vaccines for livestock, human interferons, or antibiotics, and principles from these industries were applied to the cell culture bioreactors used by the early biopharma industry ( 30 –32 ). Narrowing the range of operating conditions helped to limit the scope of experimentation needed to define a purification process with acceptable yields and purity levels for a new mAb. By 2009, many companies converged on a consensus mAb production process: cell culture in a stirred tank production bioreactor followed by harvest, Protein A affinity chromatography, viral inactivation (VI), one or two IEX chromatography steps (anion and/or cation exchange), virus filtration, and tangential-flow ultrafiltration (TFUF) to produce drug substance ( 77 , 91 , 92 ).
[54] Scaling Up Biomanufacturing: Key Steps and Industry Challenges — However, this scaling process is complex and fraught with challenges, from maintaining product quality and consistency to optimizing production efficiency. For large-scale production, it’s crucial to ensure that the cell line can maintain high productivity and product quality during the scaling process. The actual scaling up of biomanufacturing begins once the cell culture and production process has been optimized at a small scale. One of the most significant challenges in scaling up biomanufacturing is ensuring that the product remains consistent and of high quality as production scales. While biomanufacturing technology has advanced significantly in recent years, there are still limitations when it comes to scaling up certain production processes. Guardar mi nombre, correo electrónico y sitio web en este navegador para la próxima vez que haga un comentario.
[55] Scaling Up Biomanufacturing: Overcoming Challenges and Driving ... — Scaling Up Biomanufacturing: Overcoming Challenges and Driving Innovation | Stämm Scaling Up Biomanufacturing: Overcoming Challenges and Driving Innovation In the landscape of healthcare and pharmaceuticals, scaling up biomanufacturing processes is both a challenge and a crucial endeavor. Scaling up industrial biotechnology processes presents unique challenges due to small product margins, large batch sizes, inherent unpredictability, technical intricacies, and regulatory hurdles. Amidst the challenges of scaling up biomanufacturing, advancements in technology and regulatory compliance are driving innovation in the industry. Also, it mitigates risks associated with product quality and process performance during scale-up. On the other hand, scale-out offers flexibility in process design and validation strategies while accommodating varying product levels and market demands.
[56] Fast biofoundries: coping with the challenges of biomanufacturing — Metabolic engineering uses synthetic biology tools and concepts to optimize the synthesis of a target compound, from single-cell to large-scale fermentations . Synthetic biology and metabolic engineering underpin modern biomanufacturing. Bioproduction usually relies on the expression of metabolic pathways in host microorganisms in large
[57] Synthetic Biology at Scale: Less Disruption, More Cohesion — But to achieve these ambitions, synthetic biology must transition from the laboratory to commercial-scale operations. According to synthetic biology's advocates, the field is poised to overcome
[70] Biomanufacturing: history and perspective | Journal of Industrial ... — Biomanufacturing is a type of manufacturing that utilizes biological systems (e.g., living microorganisms, resting cells, animal cells, plant cells, tissues, enzymes, or in vitro synthetic (enzymatic) systems) to produce commercially important biomolecules for use in the agricultural, food, material, energy, and pharmaceutical industries. History of biomanufacturing could be classified into
[71] From Discovery to Mass Production: A Perspective on Bio-Manufacturing ... — From Discovery to Mass Production: A Perspective on Bio-Manufacturing Exemplified by the Development of Statins - ScienceDirect From Discovery to Mass Production: A Perspective on Bio-Manufacturing Exemplified by the Development of Statins The significance of bio-manufacturing can be specifically illustrated by examining the bio-manufacturing process from the scientific discovery of a key compound to its technological integration and engineering innovation. The production of the first-generation statins from microorganisms, the second-generation statins using bioconversion, and the third-generation statins through an evolution from total chemical synthesis to chemoenzymatic synthesis demonstrates the technological and engineering revolution of bio-manufacturing, which is of great importance for energy conservation, cost saving, and waste emission reduction. For all open access content, the Creative Commons licensing terms apply.
[72] Biopharmaceutical Manufacturing: Historical Perspectives and Future ... — Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search: Search Your saved search Name of saved search: Search in PubMed Add to Search Search in PubMed Add to Search The consistent and reproducible manufacturing processes of today's biopharmaceutical industry have set high standards for product efficacy, quality, and safety, and as the industry continues to evolve in the coming decade, intensified processing capabilities for an expanded range of therapeutic modalities will likely become routine. Keywords: CHO cells; Chinese hamster ovary cells; biopharmaceutical manufacturing; bioprocessing; monoclonal antibody; process development. Hummel J, et al. doi: 10.1080/19420862.2021.1903664. doi: 10.1080/19420862.2023.2191302. Search in PubMed Add to Search Search in PubMed Add to Search Search in PubMed Add to Search Add to Search
[81] Biomanufacturing - an overview | ScienceDirect Topics — Biomanufacturing is to use a biological system that consists of enzyme(s), microorganisms, or more advanced biological cells to make fuels, chemicals, nutraceuticals, pharmaceuticals, or other value-added products from renewable resources . Biomanufacturing is to use a biological system that consists of enzyme(s), microorganisms, or more advanced biological cells to make fuels, chemicals, nutraceuticals, pharmaceuticals, or other value-added products from renewable resources . For most biomanufacturing processes, fermentation in a bioreactor is the core unit, where the raw materials are converted into a target product with the catalysis by enzyme(s) or biological cells. There is an urgent need for fully controlled continuous biomanufacturing processes to make biofuels, commodity chemicals, and high-value products at significantly lower manufacturing cost.
[82] Biomanufacturing - Wikipedia — Biomanufacturing (or bioproduction) is a type of manufacturing or biotechnology that utilizes biological systems to produce commercially important biomaterials and biomolecules for use in medicines, food and beverage processing, and industrial applications. Biomanufacturing products are recovered from natural sources, such as blood, or from cultures of microbes, animal cells, or plant cells grown in specialized equipment. Several academic institutions have developed curricula and built facilities to provide education and training in biomanufacturing to students from community colleges, universities, and/or industry. Member institutions Golden LEAF Biomanufacturing Training and Education Center (BTEC) at North Carolina State University, (BRITE) at North Carolina Central University, and North Carolina Community College System’s BioNetwork operate multidisciplinary centers dedicated to workforce development for the biomanufacturing industry.
[83] What is Biomanufacturing? - Nerac — Biomanufacturing often involves recombinant DNA technology, where genetic material from multiple sources is combined to express the desired product in host cells like bacteria, yeast, or mammalian cells. Downstream processes involve the separation and purification of the bioproduct from the cell culture, ensuring that the final product is free of contaminants and meets rigorous quality standards. Beyond pharmaceuticals, biomanufacturing is also used to produce industrial enzymes used in manufacturing processes, such as in the production of biofuels, paper, and textiles. Biomanufactured products are subject to stringent regulatory requirements to ensure their safety, efficacy, and quality. As technology advances, the efficiency and cost-effectiveness of biomanufacturing processes are expected to improve, further expanding its applications and impact across diverse sectors.
[84] Biomanufacturing Trends & Technologies for the Next Decade - ISPE — Biomanufacturing Trends & Technologies for the Next Decade Antonio R. Moreira, PhD The biopharma industry is changing at a fast speed in response to the real pressures that it currently faces for producing an increasing number of complex therapeutic molecules, faster, with consistent high quality, and cost-effective manufacturing systems.
[85] Smart Manufacturing: Automating Bioproduction - Peaker Map — Gone are the days of manual processes and batch production. Today's biomanufacturing facilities are increasingly embracing automation and process control, leveraging cutting-edge technologies to achieve higher efficiency, reproducibility, and quality. Here's a closer look at how technology is reshaping biomanufacturing: 1.
[86] Automated bioprocessing - 7 advantages of automation — The biomanufacturing process is complex and requires process control, optimization, and monitoring to ensure product quality. Automation has revolutionized the bioprocessing industry, enabling real-time control of the manufacturing process, reducing variability, and improving product quality. In this article, we will explore 7 advantages of
[87] AI-Optimized Bio manufacturing: Enhancing Efficiency in Biotechnology — This article explores how AI is optimizing biomanufacturing, leading to greater efficiency, reduced costs, and improved outcomes in biotechnology . For instance, AI-driven systems can predict the most efficient ways to recycle waste products from biomanufacturing processes, turning them into valuable byproducts. AI-optimized biomanufacturing is transforming the biotechnology industry by enhancing efficiency, reducing costs, and improving product quality. The integration of AI into biomanufacturing processes not only promises to improve efficiency but also opens new possibilities for innovation in biotechnology, paving the way for a more sustainable and productive future. Journal of Biochemistry and Biotechnology received 2916 citations as per Google Scholar report
[119] Application and progress of techno-economic analysis and life cycle ... — Given the overall life cycle of the biomanufacturing process, life cycle assessment (LCA) mainly focuses on the environmental impact by considering all energy and resource inputs and multiple environmental emission outputs, instead of technical and economic feasibility and economic profitability .
[120] Greening Biomanufacturing: A Life Cycle Assessment Approach — Life cycle assessment is a valuable tool for biomanufacturers seeking to minimize their environmental impact. By understanding the full lifecycle of their products and processes, biomanufacturers can make informed decisions to reduce resource consumption, minimize waste, and contribute to a more sustainable future.
[121] Produce It Sustainably: Life Cycle Assessment of a Biomanufacturing ... — With a particular focus on CO 2 emission assessment, we demonstrated how the Life Cycle Assessment (LCA) ontological term formalization could be applied to a biomanufacturing process use case. The ontological representation of LCA allows easier comparative analysis between changes in a manufacturing arrangement and the corresponding LCA result.
[122] Scenarios for Improvement of Green Metrics for Biologics — It is hypothesized that continuous biomanufacturing will be the key element to reduce the environmental impact of biologics manufacturing processes. Studies have shown that heating, ventilation, and cooling (HVAC) energy consumption for cleanrooms is a major impact factor across all assessed impact categories .
[124] Biomanufacturing: history and perspective - PubMed — Biomanufacturing: history and perspective - PubMed Search in PubMed Search in PubMed Biomanufacturing is a type of manufacturing that utilizes biological systems (e.g., living microorganisms, resting cells, animal cells, plant cells, tissues, enzymes, or in vitro synthetic (enzymatic) systems) to produce commercially important biomolecules for use in the agricultural, food, material, energy, and pharmaceutical industries. Biomanufacturing 4.0 could focus on new products, for example, human tissues or cells made by regenerative medicine, artificial starch made by in vitro synthetic biosystems, isobutanol fermented by metabolic engineering, and synthetic biology-driven microorganisms, as well as exiting products produced by far better approaches. Keywords: Advanced biomanufacturing; Bioeconomy; Biomanufacturing 4.0; In vitro synthetic biosystem; Metabolic engineering and synthetic biology; Sustainability revolution. Search in PubMed
[125] Biomanufacturing - an overview | ScienceDirect Topics — Biomanufacturing is to use a biological system that consists of enzyme(s), microorganisms, or more advanced biological cells to make fuels, chemicals, nutraceuticals, pharmaceuticals, or other value-added products from renewable resources . Biomanufacturing is to use a biological system that consists of enzyme(s), microorganisms, or more advanced biological cells to make fuels, chemicals, nutraceuticals, pharmaceuticals, or other value-added products from renewable resources . For most biomanufacturing processes, fermentation in a bioreactor is the core unit, where the raw materials are converted into a target product with the catalysis by enzyme(s) or biological cells. There is an urgent need for fully controlled continuous biomanufacturing processes to make biofuels, commodity chemicals, and high-value products at significantly lower manufacturing cost.
[126] Microbial Fermentation in Food and Beverage Industries: Innovations ... — The Importance of Fermentation in Food Preservation, Flavor Enhancement, and Nutritional Value The process of fermentation makes proteins, carbohydrates, and fats more digestible, and nutrients in these foods are thus available to the body .
[127] Precision fermentation for producing food ingredients — This review discusses how systems metabolic engineering can be applied to precision fermentation-based production of food ingredients in microbial hosts, with a particular focus on the production of flavoring and coloring agents. Precision fermentation is a process that uses metabolically engineered micro-organisms to produce value-added food ingredients in precisely controlled environments [3•]. This process involves systems metabolic engineering to construct strains that produce food ingredients with improved performance, followed by the use of various fermentation and downstream processing technologies to obtain these products. Microbial hosts in precision fermentation should have robust metabolic flux toward the target products for high-level production of food ingredients.
[128] Precision fermentation for improving the quality, flavor, safety, and ... — Precision fermentation for improving the quality, flavor, safety, and sustainability of foods - ScienceDirect By introducing the metabolic designs, genetic modifications, and resulting products of engineered microorganisms developed through academic and industrial research, this review aims to provide insights into the potentials and challenges of precision fermentation for the economic, safe, and sustainable production of foods. Instead, we aim to provide examples that demonstrate the consumer-focused improvements precision fermentation can introduce to the industry and, at the end, to propose a new system for categorizing genetically engineered products that could refine the way we refer to, and label, engineered food products. As demonstrated by the examples presented here, precision fermentation shows incredible potential to improve the flavor, safety, and sustainability of food products across the industry, ultimately improving the overall quality of the food supply for the sake of the consumer.
[129] Microbial Fermentation in Food and Beverage Industries ... - MDPI — Research from various continents has established correlations between the microbes found in specific fermented foods, such as agave fructans, kefir, yeast, kombucha, cheeses, and vegetables, and a range of health benefits, including weight management, reduced risk of cardiovascular and gastrointestinal diseases, antidiabetic effects, relief from constipation, improved glucose and lipid levels, enhanced immunological functions, anticancer properties, and decreased mortality rates, promoting human health . Mukherjee, A.; Gomez-Sala, B.; O’Connor, E.M.; Kenny, J.G.; Cotter, P.D. Global Regulatory Frameworks for Fermented Foods: A Review. Sadh, P.K.; Kumar, S.; Chawla, P.; Duhan, J.S. Fermentation: A Boon for Production of Bioactive Compounds by Processing of Food Industries Wastes (By-Products).
[139] Adapting to Changing Consumer Preferences: Trends and Strategies - Food ... — Adapting to Changing Consumer Preferences: Trends and Strategies - Food Industry Executive Food companies must remain agile, adapting product offerings to meet diverse demographic needs through innovation, technology, and flexible strategies. The food industry is experiencing significant shifts as consumer preferences evolve, driven by a heightened focus on health, sustainability, and convenience. Whether tailoring products to different demographics, incorporating plant-based and allergen-friendly options, or leveraging technology to enhance the consumer experience, food companies have a unique opportunity to create value. Consumer preferences continue to evolve, and food companies must stay on top of these trends to remain competitive. In today’s rapidly evolving food landscape, success hinges on a company’s ability to adapt to changing consumer preferences while maintaining operational efficiency.
[140] Changing Consumer Preferences and Demand for Healthier Options — The shift in consumer preferences towards healthier, organic, and plant-based food options has become a defining trend in the global food industry. Increasing awareness about health, nutrition, and environmental impact is driving this change, prompting consumers to seek out products that align with their evolving values. For food processing companies, this transition presents a unique…
[162] Regulatory and Technical Challenges: Manufacturing of Biologics — The biopharmaceutical industry is experiencing a transformative shift from traditional fed-batch processes to Continuous Manufacturing (CM), particularly in biologics production. Each guideline addresses specific aspects of development, quality, and lifecycle management, offering a comprehensive framework to support the implementation and regulation of CM processes in the biopharmaceutical industry. Integration into Control Strategies: Ensuring that risk management is seamlessly incorporated into process control strategies helps maintain consistent product quality and compliance (17). Process Control and Monitoring: Biologics require comprehensive real-time quality and microbial contamination control, which demands sophisticated PAT for product-specific CQAs (e.g., protein aggregation). Implementing rapid testing technologies can improve real-time contamination detection, but regulatory validation of these tools for continuous processes remains challenging.
[165] Manufacturing, regulatory and commercial challenges of ... — Regulatory authorities require that all biopharmaceutical products must be manufactured according to current Good Manufacturing Practice (cGMP) guidelines .Accordingly, products must be manufactured in a reproducible and documented manner to guarantee the highest possible quality, safety and efficacy of the product .Manufacturing premises and equipment have to be located, designed
[167] EPA, FDA and USDA Issues Updates to the Joint Regulatory Plan for ... — EPA, FDA and USDA Issues Updates to the Joint Regulatory Plan for Biotechnology | US EPA EPA, FDA and USDA Issues Updates to the Joint Regulatory Plan for Biotechnology WASHINGTON – Today, May 8, 2024, in response to President Biden’s Executive Order 14081, “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy,” the U.S. Environmental Protection Agency, the U.S. Food and Drug Administration and the U.S. Department of Agriculture have developed a plan to update, streamline and clarify their regulations and oversight mechanisms for products of biotechnology. It describes the comprehensive federal regulatory policy for ensuring the safety of biotechnology products, including how EPA, the FDA and USDA share responsibility for regulating many of the products of biotechnology in the United States.
[168] Regulatory Issues and Debates in Modern Biomanufacturing — Regulatory bodies are tasked with developing frameworks that address these issues while still fostering innovation. Data integrity and compliance: Data integrity is a critical aspect of regulatory compliance in biomanufacturing. Regulatory agencies require accurate, reliable data to assess the safety and efficacy of biopharmaceutical products.
[169] PDF — regulatory science. By working together, stakeholders can address emerging challenges and drive progress in biomanufacturing. Adaptive and risk-based approaches: Adopting adaptive and risk-based regulatory approaches can help address the dynamic nature of biomanufacturing. For example, regulatory frameworks that allow for iterative assessments
[170] Regulatory Issues and Debates in Modern Biomanufacturing — Ensuring compliance with Good Manufacturing Practice (GMP) standards is vital, but the integration of new technologies can sometimes create gaps in data handling and documentation. Addressing these gaps requires continuous training, robust systems for data management and stringent validation processes to maintain high standards of data integrity.
[171] Designing Quality into Biomanufacturing - pharmasalmanac.com — Regulatory compliance is aligned with FDA and ICH guidelines under QbD, which emphasizes a science- and risk-based approach in addition to detailed documentation and proactive quality measures, thus potentially expediting regulatory reviews and approvals such as IND and BLA filings. ... and the integration of new analytical technologies. 16
[173] PDF — Ensuring compliance with these regulations is essential for maintaining product quality and avoiding regulatory penalties. Integration of advanced technologies: The integration of advanced technologies, such as Artificial Intelligence (AI) and machine learning, into process analytics presents both opportunities and challenges.
[174] Regulatory and Technical Challenges: Manufacturing of Biologics — The biopharmaceutical industry is experiencing a transformative shift from traditional fed-batch processes to Continuous Manufacturing (CM), particularly in biologics production. Each guideline addresses specific aspects of development, quality, and lifecycle management, offering a comprehensive framework to support the implementation and regulation of CM processes in the biopharmaceutical industry. Integration into Control Strategies: Ensuring that risk management is seamlessly incorporated into process control strategies helps maintain consistent product quality and compliance (17). Process Control and Monitoring: Biologics require comprehensive real-time quality and microbial contamination control, which demands sophisticated PAT for product-specific CQAs (e.g., protein aggregation). Implementing rapid testing technologies can improve real-time contamination detection, but regulatory validation of these tools for continuous processes remains challenging.
[183] The Future is Continuous: Accelerating the Shift in Biomanufacturing — Despite the obvious advantages that continuous processing has provided in other manufacturing sectors, many misunderstandings about continuous bioprocessing for biologics production persist, including that the technology is complex and difficult to implement, is not suited for large-scale production, actually adds costs rather than reducing them, is not accepted by regulatory authorities, and is only applicable for limited types of biologic drug substances.7 The conservative nature of the pharmaceutical industry — combined with these misperceptions —has resulted in a slow adoption rate, even though regulatory agencies have provided encouragement over the last decade or more.
[184] Developments and opportunities in continuous biopharmaceutical ... — Today's biologics manufacturing practices incur high costs to the drug makers, which can contribute to high prices for patients. Timely investment in the development and implementation of continuous biomanufacturing can increase the production of
[185] Scaling Up Biomanufacturing: Key Steps and Industry Challenges — However, this scaling process is complex and fraught with challenges, from maintaining product quality and consistency to optimizing production efficiency. For large-scale production, it’s crucial to ensure that the cell line can maintain high productivity and product quality during the scaling process. The actual scaling up of biomanufacturing begins once the cell culture and production process has been optimized at a small scale. One of the most significant challenges in scaling up biomanufacturing is ensuring that the product remains consistent and of high quality as production scales. While biomanufacturing technology has advanced significantly in recent years, there are still limitations when it comes to scaling up certain production processes. Guardar mi nombre, correo electrónico y sitio web en este navegador para la próxima vez que haga un comentario.
[187] Designing Quality into Biomanufacturing - pharmasalmanac.com — Quality by design (QbD) is a systematic and proactive approach to integrate quality into the biopharmaceutical manufacturing process from its inception, aiming to reduce product variability and defects, enhance development and manufacturing efficiencies, and improve overall product life cycle management. The QbD approach begins with the engineering of the biologic drug substance to possess specific properties that assure safety, efficacy, and stability, facilitating both storage and handling while optimizing manufacturability and delivery in alignment with patient population needs and desired clinical outcomes and product performance.10,12 Early development stages include rigorous risk assessments to identify and mitigate potential variabilities that could impact product quality.
[188] Quality Control and Assurance Strategies in Biopharmaceuticals — CAPA takes a systematic approach to identifying, addressing, and preventing quality issues. A robust CAPA strategy addresses immediate quality issues while contributing to long-term quality improvement and compliance. CAPA is a powerful tool in the quality toolbox that drives continuous improvement and maintains high standards.
[189] Quality Risk Management (QRM) Strategies in Life Sciences — Quality Risk Management, often abbreviated as QRM, is the systematic process of identifying, assessing, and controlling risks to the quality of products throughout their lifecycle. In the context of the life science industry, these products encompass pharmaceuticals, biologics, medical devices, and even clinical trial materials.
[206] PDF — The In a recent webinar, experts from Thermo Fisher Scientific, a global supplier of bioprocessing equipment and consumables, explored how to support the achievement of customers’ sustainability goals through product innovation, particularly around single-use technologies (SUTs). Incorporating materials and equipment optimized to lessen environmental impact in biomanufacturing is one of the key ways bioprocessing organizations can work to achieve their sustainability targets, advancing the efficiency of individual products, reducing the packaging required to transport them, establishing more regional supply chains, and promoting the recyclability of SUTs. There are a number of effective strategies pharmaceutical companies can employ to achieve greater sustainability.
[207] Biomanufacturing design: reducing the environmental burden — Directed by such rigorous analyses as life cycle assessment (LCA) and empowered by new materials, processes, and recycling designs, such burden-generating activities as energy consumption, water usage, and waste solids production can be reduced 7, 8•. When sustainability is employed as one of the formal design criteria for processes and facilities, a significant reduction of its environmental burden can arise (https://www.usgbc.org/press/benefits-of-green-building; Navigation to U.S. Green Building Council site and introduction to the Leadership in Energy and Environment Design (LEED) rating system and the recent IPCC report on the sustainable transition in land, energy, buildings, transport and cities.). https://bpsalliance.org/committees/; volunteers providing information on how single-use technologies support sustainability and how BPSA provides environmental sustainability tools in the biomanufacturing and polymer industry.).
[208] Environmental impacts and techno-economic assessments of biobased ... — Based on the review of recent literature, this study aims to provide insights into the technical feasibility, costs, and environmental impacts of biobased products produced from different renewable biogenic resources, especially in reference to their fossil-based counterparts. By identifying the bottlenecks for reduction of costs and life cycle environmental impacts and the directions for future research needed in this area, this study would be useful for stakeholders of bioeconomy including researchers, policymakers, and producers who want to achieve the costs and environmental impacts reduction goals for sustainable development of biobased products. Thus, the main objective of this review study is to provide insights into the technical feasibility, costs, and environmental impacts of bioproducts from different biobased resources in comparison with their functionally equivalent fossil-based products.
[210] EPA, FDA and USDA Issues Updates to the Joint Regulatory Plan for ... — EPA, FDA and USDA Issues Updates to the Joint Regulatory Plan for Biotechnology | US EPA EPA, FDA and USDA Issues Updates to the Joint Regulatory Plan for Biotechnology WASHINGTON – Today, May 8, 2024, in response to President Biden’s Executive Order 14081, “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy,” the U.S. Environmental Protection Agency, the U.S. Food and Drug Administration and the U.S. Department of Agriculture have developed a plan to update, streamline and clarify their regulations and oversight mechanisms for products of biotechnology. It describes the comprehensive federal regulatory policy for ensuring the safety of biotechnology products, including how EPA, the FDA and USDA share responsibility for regulating many of the products of biotechnology in the United States.
[211] PDF — Biomanufacturing for Sustainability and a Circular Bioeconomy Examples of Challenges Discussed • Aligning financial incentives and technical capabilities to move toward more sustainable practices. MARCH 2023 | 3 Biomanufacturing Workforce Development and Education Examples of Challenges Discussed • Coordinating all levels of education, including K-12, community colleges, and universities to foster equitable development of a biomanufacturing workforce. • Ensuring the biomanufacturing workforce is trained in critical skills, including data science and analytics, process engineering, quality management, technoeconomic analysis, life cycle assessment. MARCH 2023 | 4 Biomanufacturing Ecosystems, Research and Development, and Data Examples of Challenges Discussed • Translating basic science results into new applications and practical capabilities. Physical Infrastructure and Scale-Up Capacity Examples of Challenges Discussed • Establishing the physical infrastructure needed to move biomanufacturing forward.
[213] PDF — As a result, single-use technology helps contribute to sub-stantially reducing your company's overall carbon footprint.* Electricity-30% Space-38% Steelwork-62% Water-87% Cleaning material-95% Stainless steel Single-use Utilizing single-use technology can deci-sively improve the environmental footprint of biomanufacturing processes. Single-use
[214] PDF — single use facility, that the single use has a smaller carbon footprint. These technologies have become common and have the prospect to become the dominant biomanufacturing platform. • The use of single use technology in biomanufacturing is widespread • There are some advantages and disadvantages to single use technologies
[215] Biomanufacturing's Green Theme - genengnews.com — Single-use technologies, especially coupled with continuous processes, enable process intensification, reducing energy requirements and facility and carbon footprints. However, these technologies
[216] PDF — •How can single-use technology help achieve sustainability goals? 6 ... Single-use facilities GE Healthcare FlexFactory™biomanufacturing operations in Marlborough, MA, USA Natural resources Ecosystem quality Human health. Assess overall environmental impact ... carbon footprint. 2010 to 2012 LCA results
[217] Life Cycle Assessment: Biopharma SUTs - BioProcess International — In examining hundreds of combinations of product, manufacturing technology, geography, and end-of-life options, those studies consistently show that SU technology usually presents a lower overall environmental impact than traditional multiuse technologies, largely because of reduced water consumption, decreased use of cleaning chemicals, and lower energy use. BioPharm Int. 17, November 2011: S30–S38; http://www.biopharminternational.com/environmental-life-cycle-assessment-comparing-single-use-and-conventional-process-technology. BioProcess Online 2016; https://www.bioprocessonline.com/doc/single-use-technology-and-sustainability-quantifying-the-environmental-impact-0001. BioProcess Int. 7(4) 2009: 18–28; https://bioprocessintl.com/manufacturing/supply-chain/environmental-life-cycle-assessment-of-disposable-bioreactors-184138. BioPharm Int. 24 (11) 2011 : S30–S38; http://www.biopharminternational.com/environmental-life-cycle-assessment-comparing-single-use-and-conventional-process-technology. BioProcess Int. 7(2) 2009: 18–25; https://bioprocessintl.com/manufacturing/supply-chain/environmental-impact-of-single-use-and-reusable-bioprocess-systems-183572.
[218] Sustainable Biomanufacturing: Innovations in Eco-Friendly Production — In this article, we explore the innovations driving eco-friendly production in biomanufacturing, from greener raw materials and energy-efficient processes to waste reduction and carbon footprint minimization. To achieve sustainability, biomanufacturers are turning to green chemistry, energy-efficient technologies, and circular economy principles to guide their production processes. By adopting green chemistry principles, biomanufacturers can significantly reduce their environmental impact while maintaining or even improving the efficiency of their production processes. By adopting circular economy principles, biomanufacturers can minimize waste, reduce raw material consumption, and contribute to a more sustainable and efficient production model. Guardar mi nombre, correo electrónico y sitio web en este navegador para la próxima vez que haga un comentario.
[220] Continuous biomanufacturing for sustainable bioeconomy applications — Continuous biomanufacturing for sustainable bioeconomy applications - ScienceDirect Continuous biomanufacturing for sustainable bioeconomy applications open access Comprehensive literature review on continuous fermentation processes for bioeconomy applications. Description of the advantages and current industrial applications of continuous fermentation. At present, the biotechnology industry is dominated by batch and fed-batch processes and there is increasing interest in continuous biomanufacturing (CBM) as an alternative to reduce capital and operating costs. Transitioning from batch to continuous processes can enhance productivity and reduce environmental impacts, making CBM a cornerstone technology for a sustainable bioeconomy. Next article in issue No articles found. All content on this site: Copyright © 2025 Elsevier B.V., its licensors, and contributors. For all open access content, the Creative Commons licensing terms apply.
[249] The Bioprocess Revolution: How Technology and Trends are Reshaping ... — The global market for bioprocess optimization and digital biomanufacturing is expected to grow from $24.3 billion in 2024 to $39.6 billion in the coming years. 4 This growth is driven by the industry's focus on improving efficiency, reducing human error, and enabling real-time monitoring and control of bioprocesses.
[250] Next-Generation Biomanufacturing Market Trends: Drivers, Restraints and ... — Next-Generation Biomanufacturing Market Drivers. In addition, increasing effectiveness in treating various diseases and medical conditions, such as cancer, autoimmune disorders, and infectious diseases, is another factor driving revenue growth of the market.Advancements in technology, such as single-use technology, continuous bioprocessing, automation and digitalization, gene editing, and
[254] Trends in biomanufacturing and the skillsets required to address them — Trends in biomanufacturing and the skillsets required to address them | SEC Life Sciences As tech advances, regulations shift, and the push towards more personal and quick-to-market medicine accelerates, the biomanufacturing field stands at the forefront of some of the biggest changes in the life sciences sector. Communication skills are essential for effectively collaborating with cross-functional teams, such as tech and data science, and for explaining complex biomanufacturing processes to non-specialists. As the biomanufacturing industry evolves, a gap has emerged between the current skillsets of the workforce and those required to meet new industry standards and trends, and bridging this gap is crucial. Continuous investment in learning and development to ensure your teams remain technically versed and able to thrive in the changing biomanufacturing landscape is equally important.
[256] The Future of Biomanufacturing: Trends and Innovations — The Future of Biomanufacturing: Trends and Innovations – Biotechblog The Future of Biomanufacturing: Trends and Innovations The Future of Biomanufacturing: Overcoming Challenges and Embracing Innovation The Future of Biomanufacturing: Trends and Innovations Expect to see major investments and further build out of capabilities in order to support research and development with facilities, manufacturing, engineering, and regulatory capacity to enable GMP BioManufacturing. The Future of Biomanufacturing: Challenges and Opportunities The future of biomanufacturing will require an innovative and flexible approach to inactive eukaryotic, microbial, and viral organisms in a continuous operation to advance global vaccine production. With advancements in bioreactor technology, distributed production, and the integration of AI, the future of biomanufacturing looks promising. Biomanufacturing: Present And Future – Forbes
[258] The Future of Biomanufacturing: Opportunities, Challenges, and a ... — The Future of Biomanufacturing: Opportunities, Challenges, and a Strategic Path Forward - Elliott Killian The Future of Biomanufacturing: Opportunities, Challenges, and a Strategic Path Forward Biomanufacturing is at the forefront of a revolution that could transform industries, address global challenges, and strengthen national security. My latest report dives into this exciting field, outlining how collaboration between the biomanufacturing industry and the U.S. government can drive innovation, create jobs, and ensure America remains a leader in this transformative technology. Catalyzing Biomanufacturing 2025.01.19 Elliott Killian This strategy not only positions biomanufacturing as a key driver of economic growth but also strengthens the U.S. by reshoring critical supply chains, promoting sustainability, and enhancing national security. Catalyzing Biomanufacturing 2025.01.19 Elliott Killian 2025.01.19 Elliott Killian This strategy not only positions biomanufacturing as a key driver of economic growth but also strengthens the U.S. by reshoring critical supply chains, promoting sustainability, and enhancing national security. Catalyzing Biomanufacturing 2025.01.19 Elliott Killian
[261] Robots in Biomanufacturing: A Road Map for Automation of ... — Milestone 1 — Mapping a Packaging Facility from Goods-In to Goods-Out: The first step in automation is neither engagement of mechatronics engineers nor activation of engineering departments; it will start with lean-manufacturing experts in operational excellence. Milestone 4 — Engagement with Suppliers: Following the completion of the first milestone above, the biopharmaceutical industry will be ready to engage with its suppliers about the need to make robot-friendly containers that can reduce packaging waste. It has become obvious that certain issues — e.g., packaging and software standards — need to be tackled by the biopharmaceutical industry as soon as possible if we want to achieve the vision of a fully automated, robust, and environmentally friendly factory of the future by 2030.
[262] Progressing Toward Full Automation in Biomanufacturing — The bioprocess development for follow-on drug candidates, Khera emphasizes, “… willoptimize process to boost yield and productivity of the manufacturing process, and that might require increased use of automation and evaluating new digital tools and technologies such as digital twins, PAT [process analytical technology] solutions and beyond. Progressing Toward Full Automation in Biomanufacturing Comparative Deterministic Cold Storage Headspace Analysis–Multi-sourced Injectable Container Closure Systems Organic Nanoparticle-Based Drug-Delivery Systems as Alternatives to Lipid Nanoparticles Advantages of Single-Use Chromatography Systems for Downstream Processing Advancing Biotherapy Production with Continuous Manufacturing Extractable and Leachable Challenges in Lyophilized Drug Products Design Quality in Pharmaceutical Design: A Primer for Facility Executives Developments in Aseptic Processing Pushing Tech Boundaries
[263] The Bioprocess Revolution: How Technology and Trends are Reshaping ... — Industry leaders such as Danaher Corporation, Sartorius AG, and Merck KGaA have introduced innovative automated perfusion systems and bioreactors to support this trend. 11 Automation and Digital Biomanufacturing The integration of automation and digital technologies is revolutionizing bioprocessing.
[264] Automated bioprocessing - 7 advantages of automation — The biomanufacturing process is complex and requires process control, optimization, and monitoring to ensure product quality. Automation has revolutionized the bioprocessing industry, enabling real-time control of the manufacturing process, reducing variability, and improving product quality. In this article, we will explore 7 advantages of
[265] Biomanufacturing 4.0: The impact of a data-driven approach. — It integrates advanced technologies such as automation, artificial intelligence (AI), process interoperability, 3D printing, sensors for constant monitoring and control, and big data analytics to drive a more connected, transparent, and customer-centric manufacturing environment. ... Game-Changing Benefits of Biomanufacturing 4.0.
[270] The Future of Biomanufacturing: Trends and Innovations — The Future of Biomanufacturing: Trends and Innovations – Biotechblog The Future of Biomanufacturing: Trends and Innovations The Future of Biomanufacturing: Overcoming Challenges and Embracing Innovation The Future of Biomanufacturing: Trends and Innovations Expect to see major investments and further build out of capabilities in order to support research and development with facilities, manufacturing, engineering, and regulatory capacity to enable GMP BioManufacturing. The Future of Biomanufacturing: Challenges and Opportunities The future of biomanufacturing will require an innovative and flexible approach to inactive eukaryotic, microbial, and viral organisms in a continuous operation to advance global vaccine production. With advancements in bioreactor technology, distributed production, and the integration of AI, the future of biomanufacturing looks promising. Biomanufacturing: Present And Future – Forbes
[271] Next-Generation Biomanufacturing Market Size & Trends 2023-2033 — As per Future Market Insights, the next-generation biomanufacturing market is anticipated to attain a value pool of USD 20 billion by 2023-end. Global adoption for next-generation biomanufacturing is expected to rise at a CAGR of 7.2% to USD 40 billion in 2033.
[292] Biomanufacturing evolution from conventional to intensified processes ... — Process intensification has shown great potential to increase productivity and reduce costs in biomanufacturing. This case study describes the evolution of a manufacturing process from a conventional processing scheme at 1000-L scale (Process A, n = 5) to intensified processing schemes at both 1000-L (Process B, n = 8) and 2000-L scales (Process C, n = 3) for the production of a monoclonal
[294] PDF — Table 3.1 Summary of Six Sigma Implementation in Biomanufacturing Company Focus Area Main Issue Six Sigma Tools Used Improvements Achieved Key Results Amgen Recombinant Protein Production Variability In Cell Culture & Purification DMAIC, SPC, Fishbone Analysis Improved Nutrient Delivery, pH Control, Chromatography Consistent Yield, Regulatory Compliance Genentech Biologics Manufacturing Inconsistent Protein Yield In Fermentation DOE, Regression Analysis, SPC Automated Nutrient Systems, Oxygen & Temperature Control 20% Yield Increase, Defect Reduction Pfizer Vaccine Production Batch Inconsistency, Long Cycle Times Process Mapping, Control Charts Automated Formulation, Temperature & Sterilization Control Reduced Cycle Time, Improved Batch Consistency International Journal of Research Publication and Reviews, Vol 5, no 10, pp 4133-4140 October 2024 4137 Merck Biologics Quality Improvement Variability In Purity & Stability Process Flow Analysis, Control Charts Standardized Filtration, Optimized Formulation Conditions Enhanced Product Safety, Compliance Case Study 4: Merck’s Quality Improvement Initiatives Background: Merck, a global leader in biologics production, faced challenges in maintaining consistent product quality and ensuring compliance with regulatory standards.
[296] PDF — Table 3.1 Summary of Six Sigma Implementation in Biomanufacturing Company Focus Area Main Issue Six Sigma Tools Used Improvements Achieved Key Results Amgen Recombinant Protein Production Variability In Cell Culture & Purification DMAIC, SPC, Fishbone Analysis Improved Nutrient Delivery, pH Control, Chromatography Consistent Yield, Regulatory Compliance Genentech Biologics Manufacturing Inconsistent Protein Yield In Fermentation DOE, Regression Analysis, SPC Automated Nutrient Systems, Oxygen & Temperature Control 20% Yield Increase, Defect Reduction Pfizer Vaccine Production Batch Inconsistency, Long Cycle Times Process Mapping, Control Charts Automated Formulation, Temperature & Sterilization Control Reduced Cycle Time, Improved Batch Consistency International Journal of Research Publication and Reviews, Vol 5, no 10, pp 4133-4140 October 2024 4137 Merck Biologics Quality Improvement Variability In Purity & Stability Process Flow Analysis, Control Charts Standardized Filtration, Optimized Formulation Conditions Enhanced Product Safety, Compliance Case Study 4: Merck’s Quality Improvement Initiatives Background: Merck, a global leader in biologics production, faced challenges in maintaining consistent product quality and ensuring compliance with regulatory standards.
[297] Leadvent Group| Regulatory Guide for Biomanufacturing Success — Leadvent Group| Regulatory Guide for Biomanufacturing Success The regulatory codes associated with biomanufacturing are more like a safety net that allows the innovation not only to stay on the right track but also to mitigate top-tier quality and safety all at the same time. Despite the serious consequences associated with non-compliance with regulatory codes in the biomanufacturing industry, occurrences like product recalls and patient deaths are taking place. 1) Why is regulatory compliance critical in biomanufacturing? Regulatory compliance is essential for maintaining the safety, effectiveness and quality of the biomanufacturing product offerings. World Biomanufacturing Forum, 2024 with its emphasis on the regulatory codes and through thought-provoking analysis can herald a new horizon for the pharmaceutical companies.
[298] Driving Process Improvement in Biomanufacturing: Insights from Six ... — Merck, a global leader in biologics production, faced challenges in maintaining consistent product quality and ensuring compliance with regulatory standards. The company decided to implement Six Sigma as part of its broader quality improvement initiatives, focusing on improving process capability and ensuring product safety.
[303] "Ensuring Compliance in Biologics Manufacturing: The Power of ... — "Discover how regulatory intelligence can enhance compliance in biologics manufacturing. Learn about key challenges, strategies for managing regulations, and the importance of proactive planning in the life sciences industry." Find out how to use regulatory intelligence to be successful in the life science space.
[304] Overcoming Scalability in Biologics: CDMO Strategies for Success — Biopharmaceuticals CDMOs enable biotech companies to expedite the transition from preclinical development to clinical manufacturing, by leveraging their expertise in process development and scale-up manufacturing. Biotech companies need CDMOs who provide flexible manufacturing services for complex biopharmaceuticals that adapt to evolving market demands and production requirements. Biopharmaceutical CDMOs mitigate regulatory risks and uphold the highest standards of manufacturing success by adhering to stringent guidelines to ensure product safety, efficiency and quality. Biopharmaceutical CDMOs employ rigorous quality control measures to monitor and evaluate product quality throughout the manufacturing process. Biotech CDMOs offer manufacturing services for complex biopharmaceuticals, ranging from cell line development and process optimization to large-scale production, sterile fill finish and regulatory compliance.
[305] PDF — However, this rapidly evolving field faces a host of regulatory challenges and debates that impact every aspect of biomanufacturing, from product development to market approval. Description Regulatory frameworks and challenges Evolving standards and guidelines: One of the most significant regulatory challenges in biomanufacturing is the rapid pace of scientific and technological advancement. Regulatory agencies and stakeholders must grapple with these ethical considerations while developing frameworks that ensure responsible use of these technologies. Regulatory bodies and industry stakeholders are now debating how to enhance supply chain transparency and ensure the reliability of biopharmaceutical production. Conclusion Regulatory issues and debates in biomanufacturing are complex and multifaceted, reflecting the dynamic nature of the industry and the rapid pace of technological advancement.
[306] Regulatory challenges of continuous biomanufacturing - Academia.edu — Agenda Regulatory Challenges/Considerations • Myth-batch definition challenge • With new approaches and emerging technologies, engage FDA early and often • With changing regulatory environment-need internal alignment first • With legacy unique processes or products-embrace education of agency and re-education of agency reviewers • Case study-validation of hybrid continuous
[309] PDF — Table 3.1 Summary of Six Sigma Implementation in Biomanufacturing Company Focus Area Main Issue Six Sigma Tools Used Improvements Achieved Key Results Amgen Recombinant Protein Production Variability In Cell Culture & Purification DMAIC, SPC, Fishbone Analysis Improved Nutrient Delivery, pH Control, Chromatography Consistent Yield, Regulatory Compliance Genentech Biologics Manufacturing Inconsistent Protein Yield In Fermentation DOE, Regression Analysis, SPC Automated Nutrient Systems, Oxygen & Temperature Control 20% Yield Increase, Defect Reduction Pfizer Vaccine Production Batch Inconsistency, Long Cycle Times Process Mapping, Control Charts Automated Formulation, Temperature & Sterilization Control Reduced Cycle Time, Improved Batch Consistency International Journal of Research Publication and Reviews, Vol 5, no 10, pp 4133-4140 October 2024 4137 Merck Biologics Quality Improvement Variability In Purity & Stability Process Flow Analysis, Control Charts Standardized Filtration, Optimized Formulation Conditions Enhanced Product Safety, Compliance Case Study 4: Merck’s Quality Improvement Initiatives Background: Merck, a global leader in biologics production, faced challenges in maintaining consistent product quality and ensuring compliance with regulatory standards.
[310] Driving Process Improvement in Biomanufacturing: Insights from Six ... — The DMAIC (Define, Measure, Analyze, Improve, and Control) framework serves as a foundational tool for identifying areas of improvement and implementing data-driven solutions. Real-world case studies illustrate the successful application of Six Sigma, highlighting its effectiveness in reducing defect rates and streamlining clinical trial processes.
[312] The Challenges of Implementing Six Sigma and How to Overcome Them — Implementing Six Sigma can bring significant benefits to an organization, from improving efficiency and reducing defects to enhancing overall customer satisfaction. However, the road to
[313] 10 Common Challenges in Implementing Lean Six Sigma and How to Overcome ... — Solution: Invest in training programs, provide access to necessary tools and software, and allocate dedicated resources to Lean Six Sigma projects. By fostering a culture of change, providing training and resources, focusing on data-driven decision-making, and maintaining a commitment to continuous improvement, organizations can successfully navigate the Lean Six Sigma journey and achieve lasting operational excellence. Special discounted prices are now available at Lean Six Sigma Institute for professionals and students in Latin America, aimed at enhancing opportunities for growth and development. For any questions or clarifications regarding the special discounted prices for professionals and students in Latin America, please contact Lean Six Sigma Institute at info@leansixsigmainstitute.org. [ ] Lean Six Sigma Black Belt Bundle [ ] Lean Six Sigma Master Black Belt Bundle
[316] Process Intensification: The Future of Biomanufacturing Efficiency — Process Intensification: The Future of Biomanufacturing Efficiency - Stämm Process Intensification: The Future of Biomanufacturing Efficiency Enter process intensification (PI), an approach that enhances efficiency, minimizes resource use, and reduces environmental impact (Ramírez-Márquez et al., 2023). What is Process Intensification (PI)? For example, single-use technologies, such as our bubble-free bioreactors inside the Bioprocessor, further aid process intensification by eliminating the cleaning requirements of stainless-steel systems, enabling rapid changeovers and shorter production cycles. Stämm’s Bioprocessors combine advanced technologies, process integrations, and bioprocess understanding to serve the industry with a new approach to biomanufacturing. -Chemical Engineering and Processing – Process Intensification, 192, 109507. What is Process Intensification (PI)? Home » Blog » Process Intensification: The Future of Biomanufacturing Efficiency
[317] Process intensification in the biopharma industry: Improving efficiency ... — Process intensification in the biopharma industry: Improving efficiency of protein manufacturing processes from development to production scale using synergistic approaches - ScienceDirect Process intensification in the biopharma industry: Improving efficiency of protein manufacturing processes from development to production scale using synergistic approaches Implemented examples demonstrate synergistic process intensification from perfusion clone selection to production process. Rapid growth combined with increasingly diverse and challenging molecule formats in the biopharma sector necessitate strategies for fast development of highly productive and cost-efficient processes. Using monoclonal antibody production in CHO cells as example, we present intensification techniques and process sequences that deliver synergistic benefits like increasing space-time yields up to 10-fold, shortening production runs by 30%, or saving numerous days in cell expansion. Next article in issue No articles found. For all open access content, the relevant licensing terms apply.